Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Olin Q1 2026 Earnings Call - Earnings Surge Driven by Supply Shocks and Cost Discipline
Olin reported a sharp sequential earnings improvement in Q1 2026, driven by structural cost reductions from the Beyond 250 program and a global chlor-alkali supply squeeze triggered by the Iran confli...
- Q1 2026 adjusted EBITDA came in at $86 million, with management guiding to $160 million-$200 million for Q2, signaling a massive sequential earnings jump driven by pricing and volume recovery.
- The Beyond 250 structural cost reduction program delivered $44 million in savings last year and is targeting an additional $100 million-$120 million in 2026, with $250 million cumulative savings by 2028.
- Global chlor-alkali supply is severely constrained, with 6%-9% of vinyls capacity offline due to the Iran conflict, forcing Asian producers into force majeure and tightening co-produced caustic soda availability.
- +7 more takeaways
Information Services Group Q1 2026 Earnings Call - AI Governance Becomes the New Growth Engine
ISG delivered a strong first quarter, with revenue reaching $61.2 million and adjusted EBITDA rising 12% to $8.3 million. The company’s AI transformation strategy is no longer theoretical. AI-related ...
- AI revenue is accelerating fast. AI-related revenue hit $21 million in Q1, up from $12 million a year ago, now making up roughly one-third of total firm-wide revenue.
- Margin expansion continues. Adjusted EBITDA grew 12% to $8.3 million, with margins expanding over 100 basis points to 13.5% for the sixth consecutive quarter of double-digit growth.
- Record-breaking governance deal. ISG signed its largest contract ever, a multi-year agreement valued up to $17 million to govern $300 million in tech spend for a top global manufacturer, spanning up to eight years.
- +7 more takeaways
Goldman Sachs BDC (GSBD) Q1 2026 Earnings Call - Legacy Portfolio Drag Masks Strong Modern Origination
Goldman Sachs BDC navigated a volatile first quarter by leaning into its transition from a legacy book to a modern, platform-backed origination engine. While reported metrics took a hit from mark-to-m...
- Legacy vs. Modern Split: The portfolio is now 58% post-integration originations and 42% legacy positions. The modern book is performing in line with expectations with minimal non-accruals, while the legacy book accounts for roughly 72% of quarterly losses and over 99.5% of non-accruals.
- Credit Quality Distinction: Management drew a strict line between mark-to-market volatility and true credit impairment. Unrealized losses are attributed to broader spread widening, not borrower solvency issues, whereas actual credit losses are concentrated in two idiosyncratic legacy names: One GI LLC and 3SI Security Systems Inc.
- Non-Accruals Rise to 4.7%: Total non-accruals increased from 2.8% to 4.7% of the portfolio at amortized cost, driven almost entirely by the two legacy names mentioned above. New vintage originations remain sound with negligible non-accruals.
- +7 more takeaways
FIS Q1 2026 Earnings Call - Margin Expansion and AI Orchestration Drive Record Cash Flow
FIS delivered a strong start to 2026, exceeding expectations across all key financial metrics while advancing its strategic pivot toward regulated AI orchestration. Pro forma revenue grew 6.5%, adjust...
- Pro forma revenue grew 6.5%, beating the high end of management's outlook, with Banking Solutions up 7.7% and Capital Markets up 2.9%.
- Adjusted EBITDA margins expanded 87 basis points year-over-year to 39.6%, driven by favorable product mix and disciplined cost optimization.
- Free cash flow surged 111% to $474 million, already representing 23% of the full-year $2.1 billion guide, with a long-term target of over $3 billion by 2028.
- +7 more takeaways
ALX Oncology Q1 2026 Earnings Call - Evorpacept and Zanidatamab Show Durable Responses in Heavily Pretreated HER2+ Breast Cancer
ALX Oncology reported strong Q1 2026 results, highlighted by new data from its ESMO Breast Cancer 2026 presentation on evorpacept combined with zanidatamab in heavily pretreated HER2-positive metastat...
- Evorpacept plus zanidatamab achieved a 33% ORR in heavily pretreated HER2-positive metastatic breast cancer patients (median 5 prior lines), with a median DOR of 20 months and median PFS of 3.6 months.
- In the subset of 10 centrally confirmed HER2-positive patients, the ORR rose to 60%, with a median DOR of 20.2 months and median PFS of 8.3 months.
- CD47 expression emerged as a strong predictive biomarker: all 5 patients with high CD47 expression (≥20%) responded to treatment, including 1 complete response, with a median PFS of 22 months versus 3.4 months in CD47-low patients.
- +7 more takeaways
Wendy's Q1 2026 Earnings Call - China Expansion and Project Fresh Turnaround
Wendy's Q1 2026 results reflect a company in the early stages of its Project Fresh turnaround. Global system-wide sales declined 5.5%, driven by a 7.8% drop in U.S. same-restaurant sales due to traffi...
- Global system-wide sales declined 5.5% in Q1 2026, with U.S. same-restaurant sales down 7.8% due to traffic declines, weather, and operational adjustments.
- International sales grew 6%, driven by unit growth in the Philippines and Mexico, and a historic agreement to open up to 1,000 restaurants in China over the next 10 years.
- U.S. company-operated restaurants, fully implementing Project Fresh operational initiatives, outperformed the broader system by 310 basis points, validating the turnaround playbook.
- +7 more takeaways
Post Holdings Q2 2026 Earnings Call - CEO Succession and Middle East Headwinds Hold Guidance
Post Holdings delivered another quarter of strong adjusted EBITDA and cash flow generation, but management held its full-year guidance steady as new cost pressures from Middle East conflict-driven fue...
- Post Holdings Q2 adjusted EBITDA beat expectations, though full-year guidance was held flat due to new macro headwinds.
- CEO Rob Vitale steps down after 12 years; COO Nico Catoggio takes the helm, signaling continuity in capital allocation and operational discipline.
- Fiscal year-to-date share count reduced by 15% via aggressive buybacks, supported by robust free cash flow.
- +9 more takeaways
Innospec Q1 2026 Earnings Call - Fuel Specialties Drives Growth Amid Geopolitical Headwinds and Plant Disruptions
Innospec reported a mixed first quarter of 2026, with total revenues rising 3% year-over-year to $453.2 million, while adjusted EBITDA fell to $43.7 million from $54 million a year ago. The results we...
- Total revenues rose 3% year-over-year to $453.2 million, though adjusted EBITDA declined significantly to $43.7 million from $54 million a year ago, reflecting margin pressure and operational disruptions.
- Fuel Specialties remained the standout performer with 7% revenue growth to $181.6 million and gross margins holding at 35.4%, driven by a 10% volume increase and favorable currency impacts.
- Performance Chemicals faced severe headwinds from the January U.S. winter storm, which forced the shutdown of North Carolina plants, leading to a 46% drop in operating income to $10.7 million despite flat revenues.
- +7 more takeaways
Barings BDC Q1 2026 Earnings Call - Defensive Portfolio Holds Firm Amid Private Credit Dispersion
Barings BDC delivered stable net investment income of $0.25 per share in Q1 2026, despite a modest NAV decline driven by a legacy MVC write-down and realized losses on portfolio exits. The company mai...
- Q1 2026 Net Investment Income (NII) was $0.25 per share, down from $0.27 in Q4 2025, due to a slight dip in weighted average yield, fewer calendar days, and absence of Q4 one-time fees.
- NAV per share declined 0.6% to $11.02, primarily driven by a write-down in a legacy MVC asset and net realized losses of $10.8 million from exits and restructurings.
- The board maintained the quarterly dividend at $0.26 per share, yielding 9.4% on current NAV, supported by approximately $0.79 per share in spillover income.
- +7 more takeaways
Burford Capital Q1 2026 Earnings Call - Core Business Cash Flow Dwarfs YPF Reversal
Burford Capital’s first quarter 2026 results were dominated by a non-cash write-down following the Second Circuit’s reversal of a historic YPF judgment. Management framed the loss as an idiosyncratic ...
- Burford Capital recorded a significant non-cash write-down after the Second Circuit reversed a favorable YPF judgment, but management emphasized the investment has already generated over $100 million in cash profit.
- The company plans to pursue the same claims through international arbitration, noting Argentina has lost 86% of over 50 Bilateral Investment Treaty arbitrations brought against it.
- Core business remains the primary focus, with a diversified portfolio of approximately 900 active cases expected to produce billions in future cash flows.
- +7 more takeaways